Inclusion Criteria:  LVEF≤40％; NYHA II-IV; Received maximally tolerated guideline-directed medical therapy ( GDMT) for at least 3 months before enrollment; Angiography or coronary CT within 6 months shows that there is no indication for PCI / CABG; Or PCI / CABG indications, but refused.  Exclusion Criteria:  Severe valvular heart disease, congenital heart disease, acute viral myocarditis and acute coronary syndrome. PCI / CABG, ICD / permanent pacemaker / CRT implantation within 3 months. Recent cerebrovascular disease (<6 months). eGFR<30ml/min, or ALT/AST>120U/L. Hematologic disease: anemia (hemoglobin ≤9.0 g/dL); leukopenia (<3500/μL); thrombocytopenia (<70000/μL); myeloproliferative disorders, myelodysplastic syndrome, acute or chronic leukemia, and plasma cell dyscrasias (multiple myeloma, amyloidosis) . Malignant tumor within 5 years. Life expectancy <1 year according any disease. Uncontrolled acute infectious diseases. Known or suspected of being sensitive to the study drugs or its ingredients. Not suitable for inclusion according to the evaluation of the sponsors or unwilling to comply with the study protocol.